Marketed unapproved drugs workshop
A public workshop for businesses marketing unapproved drugs will be hosted by FDA Jan. 9. FDA will provide clarification and direction to companies on how to seek drug approval; topics slated for the meeting include NDAs, ANDAs, OTC monographs, application processes, user fees and market exclusivity. The agency is convening the meeting because many companies sought clarification following the June 2006 publication of the agency's Marketed Unapproved Drugs-Compliance Policy Guide (1"The Pink Sheet" June 12, 2006, p. 10)...
You may also be interested in...
FDA is encouraging manufacturers of marketed but unapproved drugs to voluntarily submit applications by highlighting the possibility of a de facto exclusivity period for sponsors who receive NDA approval for a drug that other firms are marketing without approval
The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.